Description
KPV is a synthetic tripeptide consisting of the sequence Lys-Pro-Val (K-P-V), corresponding to the C-terminal tripeptide region of α-melanocyte-stimulating hormone (α-MSH residues 11-13). α-MSH is the endogenous hormone derived from POMC (pro-opiomelanocortin) processing that mediates melanocortin receptor signaling and is known for its diverse roles in pigmentation, energy balance, and immune signaling research. KPV has been investigated in academic literature as the minimal active tripeptide fragment retaining some of α-MSH’s reported research properties without binding to the classical melanocortin receptors (MC1R, MC3R, MC4R, MC5R) — making it a useful research compound for dissecting melanocortin-independent activity of α-MSH fragments. The compound has been studied for cytokine pathway research (TNF-α and IL-6 expression endpoints), NF-κB signaling cascade markers, and comparative pharmacology versus full-length α-MSH and other melanocortin-class research peptides (Catania, Lipton, and colleagues). KPV is used here primarily as a research tool for α-MSH fragment pharmacology and structure-activity relationship (SAR) studies of melanocortin C-terminal sequences.
Benefits (Research Focus)
• α-MSH fragment pharmacology — studied as the minimal C-terminal tripeptide of α-melanocyte-stimulating hormone
• Cytokine pathway research — investigated for TNF-α and IL-6 gene expression endpoints in cell research models
• NF-κB signaling research — explored for transcription factor activation and nuclear translocation in cell research
• Melanocortin-independent activity — examined for activity not mediated through classical melanocortin receptors (MC1R-MC5R)
• Comparative SAR research — researched alongside full-length α-MSH and other melanocortin C-terminal peptide research compounds
What Researchers Look At
• TNF-α, IL-6, and other cytokine gene expression panels in cell research models
• NF-κB pathway activation, IκB phosphorylation, and nuclear translocation studies
• Comparative pharmacology versus α-MSH full-length peptide and melanocortin-targeted research compounds
• Tripeptide stability, pharmacokinetics, and peptidase resistance research
• Comparative cell viability and signaling endpoints across cell research model types
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 10 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: KPV (Lys-Pro-Val tripeptide)
• Synonyms: α-MSH(11-13); melanocortin C-terminal tripeptide; Lys-Pro-Val fragment
• Class: Synthetic tripeptide; α-MSH C-terminal fragment; melanocortin-related research compound
• Sequence: Lys-Pro-Val (K-P-V) — 3 amino acids; corresponds to α-MSH residues 11-13
• Origin: Synthetic α-MSH C-terminal tripeptide; melanocortin fragment research compound
• Formula / M.W.: ~384.5 g/mol (verify exact formula and salt form against batch COA — published values vary based on free acid versus C-amidated versus salt forms)
• CAS: 27210-24-0
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• KPV 10mg Janoshik Verification — October 9, 2025
• KPV 10mg Janoshik Verification — July 1, 2026 – Batch# KP06-0710
• KPV 10mg Janoshik Verification — Sep 25, 2026 – Batch# KP09-0810
This product has Sterility Testing
• KPV 10mg Janoshik Verification — July 14, 2026 – Batch# KP06-0710
